tetano
Editor, Senior Moderator
Front Immunol
. 2025 Mar 5:16:1550279.
doi: 10.3389/fimmu.2025.1550279. eCollection 2025. Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study
Masaya Fujitani[SUP] #[/SUP][SUP] 1 [/SUP], Xiuyuan Lu[SUP] #[/SUP][SUP] 2 [/SUP], Ryo Shinnakasu[SUP] #[/SUP][SUP] 3 [/SUP], Takeshi Inoue[SUP] 3 [/SUP], Yujiro Kidani[SUP] 1 [/SUP], Naomi M Seki[SUP] 1 [/SUP], Satoru Ishida[SUP] 1 [/SUP], Shungo Mitsuki[SUP] 1 [/SUP], Takeshi Ishihara[SUP] 1 [/SUP], Miwa Aoki[SUP] 1 [/SUP], Akio Suzuki[SUP] 1 [/SUP], Koji Takahashi[SUP] 1 [/SUP], Masahiro Takayama[SUP] 4 [/SUP], Takeshi Ota[SUP] 4 [/SUP], Satoshi Iwata[SUP] 5 [/SUP], Risa Yokokawa Shibata[SUP] 6 [/SUP], Takuhiro Sonoyama[SUP] 6 [/SUP], Mari Ariyasu[SUP] 6 [/SUP], Ayumi Kitano[SUP] 7 [/SUP], Tommy Terooatea[SUP] 7 [/SUP], Jordan Kelly Villa[SUP] 7 [/SUP], Kazuo Yamashita[SUP] 7 [/SUP], Sho Yamasaki[SUP] 2 8 9 [/SUP], Tomohiro Kurosaki[SUP] 3 9 [/SUP], Shinya Omoto[SUP] 1 [/SUP]
Affiliations
Background: The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease.
Methods: This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity.
Results: Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity.
Conclusion: These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).
Keywords: COVID-19 vaccine; S-268019-b; SARS-CoV-2; humoral immunity; immunogenicity; neutralizing antibodies; repertoire analysis; single-cell analysis.
. 2025 Mar 5:16:1550279.
doi: 10.3389/fimmu.2025.1550279. eCollection 2025. Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study
Masaya Fujitani[SUP] #[/SUP][SUP] 1 [/SUP], Xiuyuan Lu[SUP] #[/SUP][SUP] 2 [/SUP], Ryo Shinnakasu[SUP] #[/SUP][SUP] 3 [/SUP], Takeshi Inoue[SUP] 3 [/SUP], Yujiro Kidani[SUP] 1 [/SUP], Naomi M Seki[SUP] 1 [/SUP], Satoru Ishida[SUP] 1 [/SUP], Shungo Mitsuki[SUP] 1 [/SUP], Takeshi Ishihara[SUP] 1 [/SUP], Miwa Aoki[SUP] 1 [/SUP], Akio Suzuki[SUP] 1 [/SUP], Koji Takahashi[SUP] 1 [/SUP], Masahiro Takayama[SUP] 4 [/SUP], Takeshi Ota[SUP] 4 [/SUP], Satoshi Iwata[SUP] 5 [/SUP], Risa Yokokawa Shibata[SUP] 6 [/SUP], Takuhiro Sonoyama[SUP] 6 [/SUP], Mari Ariyasu[SUP] 6 [/SUP], Ayumi Kitano[SUP] 7 [/SUP], Tommy Terooatea[SUP] 7 [/SUP], Jordan Kelly Villa[SUP] 7 [/SUP], Kazuo Yamashita[SUP] 7 [/SUP], Sho Yamasaki[SUP] 2 8 9 [/SUP], Tomohiro Kurosaki[SUP] 3 9 [/SUP], Shinya Omoto[SUP] 1 [/SUP]
Affiliations
- PMID: 40109335
- PMCID: PMC11919840
- DOI: 10.3389/fimmu.2025.1550279
Background: The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease.
Methods: This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity.
Results: Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity.
Conclusion: These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).
Keywords: COVID-19 vaccine; S-268019-b; SARS-CoV-2; humoral immunity; immunogenicity; neutralizing antibodies; repertoire analysis; single-cell analysis.